AbbVie trims 2026 earnings outlook on Apogee Therapeutics deal

AbbVie cut its full-year 2026 earnings guidance on July 31 to account for its pending acquisition of Apogee Therapeutics.

The company said the lowered outlook reflects the expected financial impact of the Apogee deal, which it is pursuing to expand its immunology and inflammation portfolio, according to its announcement.

AbbVie, which trades on the New York Stock Exchange under the ticker ABBV, did not disclose the size of the guidance reduction, the deal's financial terms, or its expected closing date. Apogee is a clinical-stage biotech developing antibody therapies for inflammatory diseases.

The guidance cut is likely to weigh on AbbVie's shares in the near term as investors reassess near-term profitability. Longer term, the acquisition could strengthen AbbVie's pipeline in immunology and inflammation, a franchise where it competes with Johnson & Johnson and Bristol Myers Squibb, and the move may signal continued consolidation across the biotech sector.

The reduction comes as AbbVie works to offset declining revenue from Humira, its blockbuster arthritis drug that lost patent protection, by building out newer immunology treatments. Apogee's pipeline, focused on inflammatory conditions, would add to that effort. The company has leaned on its immunology franchise, which includes Skyrizi and Rinvoq, to drive growth as Humira sales fade.

The deal also carries sector-wide implications. Biotech M&A has picked up as large pharma companies seek growth assets to replace expiring patents, and AbbVie's move fits that trend. Investors will watch for further details on the transaction, including the purchase price and the expected impact on earnings per share once the deal closes.

For AbbVie holders, the guidance cut signals management is prioritizing long-term pipeline growth over near-term profit. The next catalyst is the company's next earnings call, where executives are expected to provide an updated outlook and more detail on the Apogee integration.

This article is for informational purposes only and does not constitute investment advice.